Ranbaxy signs licensing, supply agreement for the Canadian market

By Elaine Rigoli

Tampa, Fla., July 19 - Ranbaxy Laboratories Ltd. said the company's wholly owned subsidiary, Ranbaxy Pharmaceuticals Canada Inc., and Janssen-Ortho Inc. have entered into a licensing and supply agreement for a generic version of Risperidone compressed tablets, sold under Ranbaxy's label, Ran Risperidone.

The company said it is the first Indian company to market a licensed generic product in Canada.

The Canadian patent for Risperdal (Risperidone) expired this month. Ran Risperidone is now available through pharmacies and wholesalers.

The product is classified as a psychotherapeutic drug indicated for the management of the manifestations of psychotic disorders.

Ranbaxy has headquarters in Haryana, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.